Ovarian cancer – discover the symptoms, causes, and prognosis. Learn about diagnosis and treatment, and what to look for when symptoms first appear.
Table of Contents
- Ovarian cancer – what is it? The most important information about the disease
- Main causes and risk factors of ovarian cancer
- Most common symptoms of ovarian cancer – what to pay attention to?
- Diagnostics for ovarian cancer – what tests should be performed?
- Modern treatment methods for ovarian cancer
- Prognosis and prevention – how to improve your odds?
Ovarian cancer – what is it? The most important information about the disease
Ovarian cancer is a malignant tumor originating from ovarian cells, one of the organs of the female reproductive system. Due to its location and lack of clear, characteristic symptoms in the early stages, it’s often called the “silent killer” – it develops slowly and insidiously, not giving symptoms that are easy to catch by either patients or doctors for a long time. Medically, several types of ovarian cancer are distinguished, the most common being epithelial ovarian cancer, accounting for over 90% of all cases. Other types, such as germ cell tumors or tumors of the sex cord-stromal origin, are much rarer and mainly affect younger women. Most ovarian tumors develop after menopause, but incidence also appears in younger women, especially those with a positive family history or hereditary genetic mutations such as BRCA1 and BRCA2. Of note, as many as 3 out of 4 cases of ovarian cancer are detected at an advanced stage when the disease process is already significantly spread, which directly affects prognosis and chances of a cure. Ovaries are often referred to as “silent guardians” of every woman’s hormonal health, as they are responsible not only for fertility but also for hormonal balance, metabolic processes, and maintaining bone health. Therefore, understanding the nature of tumors affecting these organs is extremely important for public health awareness.
Ovarian cancer belongs to the group of malignant neoplasms that develop within the female gonads and are characterized by a high degree of biological aggressiveness – this means cancer cells have a tendency for rapid growth, invasion of neighboring tissues, and formation of metastases, especially within the abdominal cavity but also to distant organs such as the lungs or liver. The etiology of ovarian cancer is multifactorial – it includes genetic, hormonal, environmental factors, as well as individual lifestyle. Apart from hereditary mutations, other main risk factors include age (the highest incidence is observed after the age of 50), infertility, nulliparity, early onset of menstruation and late menopause, obesity, long-term hormonal stimulation, and certain comorbidities such as endometriosis. There are several histopathological subtypes of ovarian cancer – the most commonly seen are serous carcinoma, endometrioid, mucinous, and clear-cell carcinomas; each differs in clinical course and response to treatment. From the medical perspective, ovarian cancer is staged according to the FIGO classification, which is crucial for planning therapy and assessing the prognosis – the stage depends on the tumor size, invasion of tissues, and spread to lymph nodes or distant organs. A major challenge in modern oncology is the ability to detect ovarian cancer at an early stage – there are currently no widely available, effective screening tests, so knowledge of risk factors and raising awareness among women is key. Due to the nature of the organ, developing tumors remain asymptomatic for a long time, while in advanced stages they can cause a range of non-specific symptoms such as abdominal pain, bloating, a feeling of fullness, rapid fatigue, or weight loss. Ovarian tumors are a serious health problem – in Poland, several thousand new cases are diagnosed annually, and mortality from this disease is among the highest of all gynecological cancers. Despite advances in diagnostic and combined treatment methods, 5-year survival rates remain relatively low, underscoring the importance of prevention, education, and striving for early detection of the disease.
Main causes and risk factors of ovarian cancer
Ovarian cancer is a disease of complex etiology in which it’s impossible to identify just one specific cause. Modern medicine highlights the role of many risk factors acting on genetic, hormonal, and environmental levels. The greatest importance in the development of ovarian cancer is attributed to genetic predispositions, as confirmed by numerous studies on the inheritance of BRCA1 and BRCA2 gene mutations – these are responsible for 10-15% of all ovarian cancer cases. Women with these mutations have several times higher risk, making family history, especially of ovarian cancer and breast cancer, very important. A history of cancer among close maternal relatives may increase the probability of developing ovarian cancer several times. Apart from BRCA mutations, rarer changes in other genes, such as those involved in Lynch syndrome (mutations in MSH2, MLH1, MSH6 or PMS2), also predispose to this type of cancer. Alongside the genetic component, hormonal factors play an important role. Long-term exposure to estrogen, unbalanced by progesterone, increases the risk of cancer, which is seen in women who start menstruating very early or finish much later, and in women who’ve never given birth or have undergone ovulation-stimulating treatments. Conversely, prolonged use of oral contraceptive pills may reduce ovarian cancer risk, as supported by years of population-based studies. Epidemiological analyses also show that age is a key factor – the peak incidence is after age 50 and especially after menopause. Some studies also suggest a link between obesity and increased probability of developing ovarian cancer, as excess body fat contributes to chronic inflammation and affects the metabolism of sex hormones, including estrogen. Infertility and nulliparity are also relevant, with women who have never had children statistically being at higher risk than those with more term pregnancies.
Environmental and lifestyle factors also contribute to increased ovarian cancer risk. Although not all mechanisms are fully understood, it has been observed that exposure to certain chemicals, including talc in intimate areas, may slightly increase the risk. There are also reports suggesting that long-term hormonal therapy during menopause may increase the probability of cancer, especially with combined estrogen–progestin therapy. Chronic inflammation in the pelvic area can also increase risk – persistent inflammations, infections, or endometriosis can cause changes in the ovarian epithelium promoting malignant transformation. Another, though less significant, risk factor is exposure to ionizing radiation, e.g., during repeated radiological examinations, though the actual impact risk is small. Dietary and lifestyle factors are also important – a diet high in animal fats, calorie-dense with low fiber and antioxidants, may negatively affect ovarian health. Smoking is not considered a strong factor for epithelial ovarian cancer but may play a role in less common subtypes. In summary, the development of ovarian cancer is influenced by many factors, both beyond our control – like genes and age – and environmental or lifestyle-related, which can be mitigated to some extent by appropriate prevention, dietary modifications, and regular gynecological check-ups, especially if any of the above-mentioned risk factors are present.
Most common symptoms of ovarian cancer – what to pay attention to?
Ovarian cancer is considered one of the most insidious gynecological cancers, partly because its early symptoms are highly non-specific and characteristic. Most cases are diagnosed only when the disease is already advanced – this is why it’s so important to be aware of possible warning signs. Initially, symptoms can be very mild or even unnoticeable, and are often attributed to ordinary digestive or urinary complaints. The most common early symptoms of ovarian cancer include bloating, occasional abdominal or pelvic pain, rapid feeling of fullness when eating, digestive issues, and a general sense of discomfort in the abdominal area. Many women also experience appetite disturbances, leading to both weight loss and occasional weight gain due to fluid accumulation (ascites). Another commonly reported symptom is repeated urinary urgency, increased frequency of urination, as well as urinary incontinence or pain upon urination, which can be confused with urinary tract infections. A symptom that should raise particular suspicion is chronic fatigue, weakness, and a mysterious loss of energy – although non-specific, if persistent, they warrant further diagnostic investigation.
Advanced stages of ovarian cancer may bring a series of additional, often more pronounced symptoms. One of the most difficult and alarming signs is abdominal swelling, usually caused by either fluid build-up in the peritoneal cavity or a growing tumor mass. Some women also experience pain in the lower back, radiating to the thighs or crotch. Bowel habit changes such as frequent constipation, diarrhea or irregular bowel movements are also possible and are usually interpreted as stress or an improper diet. Other warning symptoms include irregular vaginal bleeding, bleeding between periods or after menopause, and discharge resembling pus or blood from the vagina. Furthermore, advanced disease may provoke shortness of breath, breathlessness on exertion, shoulder pain or leg swelling as a result of metastases or tumor pressure on specific anatomical structures. It’s important to remember that each woman can experience different combinations of these symptoms, and their severity does not always reflect the degree of disease advancement. Thus, even mild and seemingly trivial but chronic or unusual complaints in the pelvis and abdomen should be consulted with a gynecologist. Regular attention to one’s body and prompt response to changes in well-being increase the chance of earlier detection of this dangerous tumor.
Diagnostics for ovarian cancer – what tests should be performed?
Ovarian cancer diagnostics is a complicated, multistep process requiring the cooperation of multiple specialists and the use of modern imaging and laboratory tests. Initial diagnostics usually begin with a detailed medical interview and gynecological examination to assess the patient’s general condition, identify any changes in reproductive organs, and recognize risk factors such as family history of ovarian or breast cancer. The next important step is a transvaginal ultrasound (TVUS), which allows evaluation of ovarian morphology, the presence of cysts, nodules, or other pelvic abnormalities. Special attention is paid to morphological features like size, presence of septations, papillae, vascularization, or solid structure, which may indicate malignancy. Additionally, the doctor may order a classic transabdominal abdominal ultrasound, especially to check the stage of the disease and to look for metastases in the liver, lymph nodes, or peritoneal cavity.
Beyond imaging, an important aspect of ovarian cancer diagnosis is the testing of tumor markers in blood, of which the most significant is CA-125. A significant increase in this protein, while not specific only to ovarian cancer, can be a strong warning signal, especially in postmenopausal women or those with a positive family history. To gain a more complete picture, other markers, including HE4 (Human Epididymis Protein 4) are increasingly measured, and the ROMA (Risk of Ovarian Malignancy Algorithm) index is calculated, which assesses individual cancer risk based on combined marker results and the patient’s hormonal status. However, it should be noted that these markers may give false-positive results, e.g., in endometriosis, fibroids, or inflammatory states, so they are not a standalone basis for diagnosis. In unclear cases or when advanced changes are suspected, further advanced imaging such as CT, MRI, or PET-CT is necessary, allowing precise determination of tumor location, extent, and any metastases to other organs. Laboratory tests are also essential, including a blood count, liver and kidney function, and assessment of general body performance, which helps determine if the patient can qualify for surgery or chemotherapy. When confirmation is required, a diagnostic procedure – usually laparoscopy or laparotomy – is performed, during which tissue samples are collected for histopathological examination. Only the microscopic analysis result enables final confirmation of the nature of the lesion and the histological tumor type, which is pivotal in establishing the further treatment strategy. In some centers, especially in women with a family burden, molecular genetic tests for BRCA1, BRCA2, and other genes predisposing to ovarian cancer are also performed, which may affect not only the choice of treatment but also preventive recommendations for the patient and her relatives. It should be emphasized that the entire diagnostic process requires an individual approach and close teamwork, and the period from the onset of first symptoms to a definite diagnosis is critical to the prognosis and treatment effectiveness.
Modern treatment methods for ovarian cancer
Treatment of ovarian cancer is a dynamically developing field of gynecological oncology, where modern technologies and molecularly targeted therapies now play an increasing role. The primary and most effective treatment remains surgery, aiming for the most complete possible removal of cancerous lesions, both primary tumor foci and any metastases within the abdominal cavity. Typically, a so-called complete cytoreduction is performed, involving removal of the ovaries, uterus, fallopian tubes, greater omentum, and, if necessary, fragments of other organs. The effectiveness of the surgery depends not only on the surgical team’s experience but also on accurate assessment of disease extent, which often requires the use of intraoperative imaging methods. After surgery, most patients qualify for adjunctive treatment, mainly chemotherapy, aimed at destroying any remaining cancer cells and minimizing the risk of recurrence. The most commonly used regimens combine platinum derivatives (e.g., carboplatin) and taxanes (e.g., paclitaxel), known for high efficacy against ovarian cancer cells. For patients not eligible for surgery or those with relapses, chemotherapy remains fundamental, and in recent years, drugs targeting specific molecular abnormalities are increasingly used. Targeted therapy is gaining increasing importance, especially for women with BRCA1/2 mutations or other genetic abnormalities that are suitable targets for PARP inhibitors (e.g., olaparib, niraparib, rucaparib). PARP inhibitors act by blocking DNA repair mechanisms within tumor cells which leads to their death and inhibition of tumor growth. These drugs, administered both as maintenance treatment after chemotherapy and for recurrences, significantly prolong progression-free survival and improve overall prognosis. Another breakthrough is the use of monoclonal antibodies such as bevacizumab, which inhibits angiogenesis – the formation of new blood vessels necessary for tumor nourishment. Biological therapies are increasingly part of combination treatments, increasing the effectiveness of classical therapies and allowing individualization of the treatment process according to the patient’s molecular profile.
Promising approaches also include innovative immunotherapeutic strategies, which involve activating the immune system to fight cancer cells. Although immunotherapy for ovarian cancer is still in clinical trials, preliminary data suggest that immunomodulating drugs and therapies using immune checkpoint inhibitors (e.g., pembrolizumab) may find application in selected patient groups, especially with relapsed or treatment-resistant disease. Modern oncology is also developing methods of intraperitoneal drug delivery, allowing higher concentrations of chemotherapeutics directly at the tumor site, which can improve treatment efficiency and reduce systemic side effects. Supportive care also plays a major role – nutritional support, physiotherapy, pain management, as well as psychological support and coordination of care within a multidisciplinary team. Personalized medicine, including genetic tumor profiling, allows therapy to be tailored to individual patient features and ongoing monitoring of treatment effectiveness, resulting in better chances for long-term remission. For ovarian cancer at high risk of relapse, maintenance protocols, including long-term administration of PARP inhibitors or monoclonal antibodies to maintain therapeutic response and delay disease progression, are increasingly used. Modern treatment methods are expanding the landscape of interventions. Thanks to clinical research progress, new strategies are emerging, such as anticancer vaccines, RNA-based therapies, and future combined therapies, offering hope for even more effective treatment in the near future. Continuous monitoring of the patient’s status, regular tumor marker checks, and advanced imaging allow early detection of recurrence or progression. Ultimately, the choice of treatment always depends on the disease stage, the patient’s overall condition, the presence of specific gene mutations, and previous response to therapy. Thanks to modern methods, more and more women with ovarian cancer are able to undertake effective and individualized therapy, significantly improving their prognosis and quality of life.
Prognosis and prevention – how to improve your odds?
The prognosis for ovarian cancer depends on many factors, the most important being the advancement of the disease at the time of diagnosis, histopathological type, age, general health, and the presence of certain genetic mutations – particularly BRCA1 and BRCA2. Unfortunately, the lack of clear symptoms in early stages means that as many as 70–75% of cases are diagnosed at an advanced stage (FIGO III-IV), by which time the disease has spread beyond the ovaries and the 5-year survival rate is only 20–30%. By comparison, if detected when confined to the ovaries (stage I), the 5-year survival rate can be as high as 90%. The histopathological type also plays a crucial role – highly differentiated carcinomas are less aggressive and easier to treat than poorly differentiated ones. In recent years, treatment outcomes have improved thanks to advances in surgery, chemotherapy, and targeted therapies. Nonetheless, rapid diagnosis, appropriate treatment qualification, and tight interdisciplinary medical cooperation remain crucial. Long-term prognosis is also affected by general health, the presence of comorbidities, organ function, and nutritional status. Younger age is a favorable prognostic factor, as is complete resection of the tumor during surgery. Molecular factors are also critical: mutations in genes predisposing to ovarian cancer not only increase cancer risk, but also impact treatment choices – the presence of a BRCA mutation increases the effectiveness of PARP inhibitors and improves chemotherapy response. The course of the disease may also depend on the response to first-line therapy and overall clinical trajectory. Unfortunately, recurrences are frequent and may require repeated treatment cycles or palliative care; therefore, comprehensive care and motivation to implement preventive measures are essential.
Ovarian cancer prevention is a challenge due to the lack of effective screening tests for early detection of cancerous changes. Nevertheless, there are a number of actions that can significantly increase the chance of avoiding the disease or reduce the likelihood of a late diagnosis. Awareness of individual risk is of fundamental importance – especially in women with genetic predisposition. Women with a family history of ovarian, breast, or colon cancer are advised to undergo genetic counseling and testing for BRCA1, BRCA2, or other genes related to hereditary cancer syndromes (Lynch, RAD51C/D). In case of confirmed hereditary risk, prophylactic procedures such as preventive salpingo-oophorectomy (removal of ovaries and fallopian tubes) after family planning may be considered; this significantly reduces the risk of ovarian and breast cancer. Guidelines also recommend regular gynecological examinations with transvaginal ultrasound, though not formal screening, these help in assessing ovarian structure in high-risk women. Taking oral hormonal contraceptives for several years has proven to have a protective effect, reducing ovarian cancer risk by around 30–50%, though the decision to use them should always be discussed case-by-case with a physician. Limiting environmental and lifestyle risk factors is also important: avoiding smoking, maintaining a healthy weight, regular physical activity, and a balanced, low-animal fat diet may help lower risk. Women with infertility and prolonged hormonal stimulation should stay under close medical supervision, as should women who’ve never been pregnant or those experiencing early menopause. Alongside specific prevention, “secondary prevention” is essential – early recognition of symptoms, regular gynecological consultations, and promptly seeking medical advice for unusual complaints; only such vigilance allows for detection in a phase where the disease is still fully curable and offers the best long-term outlook.
Summary
Ovarian cancer is an insidious neoplasm that often presents with non-specific symptoms, leading to late diagnosis. Early diagnostics and a prompt reaction to alarming symptoms are crucial for effective treatment and a better prognosis. Being aware of risk factors and symptoms of ovarian cancer helps maintain health awareness and regularly perform necessary tests. Modern treatment methods make fighting this cancer more effective than ever, while proper prevention is vital in reducing the risk of falling ill. Remember, an early visit to the gynecologist in the case of alarming complaints increases your chances for early detection and effective therapy.
